PRNewsWire
19 Mar 2026, 13:00 UTC · 34w ago
AQST Investor Alert: AQUESTIVE THERAPEUTICS, INC. Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Analyst Slashed Price Target: SueWallSt
Impact · against what's priced in
AQST faces a severe valuation reset due to FDA deficiencies that halted labeling discussions for Anaphylm and sparked a securities fraud lawsuit. AGCO and MYGN are under investigation for forecast cuts and margin misses, respectively, adding governance and execution risks to their outlooks.
- AQST−0.90
No priced-in read yet





